SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2026

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Schedule of estimated useful lives of property, plant and equipment

The Company's property, plant, and equipment primarily consists of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:


Production equipment		3 to 13 years
Office furniture and equipment		3 to 10 years
Buildings		39 years
Building improvements		5 to 15 years

Schedule of significant customers

The following table reflects the Company’s significant customers for the three and six month periods ended June 30, 2026 and 2025:


		Three Months Ended					Three Months Ended					Six Months Ended					Six Months Ended
		June 30, 2026					June 30, 2025					June 30, 2026					June 30, 2025
Number of significant customers			2					3					2					3
Aggregate dollar amount of net sales to significant customers		$	3.5	million			$	6.0	million			$	6.9	million			$	10.3	million
Percentage of net sales to significant customers			49.1%					57.2%					48.1%					55.0%

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized

Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:


		For the three months ended June 30, 2026:
					Blood									Total
					Collection			EasyPoint^®			Other			Product
Geographic Segment		Syringes			Products			Needles			Products			Sales
U.S. sales		$	5,299,242			294,940			272,174			7,164			5,873,520
North and South America sales (excluding U.S.)			829,832			—			347,092			—			1,176,924
Other international sales			121,478			1,000			27,152			549			150,179
Total		$	6,250,552		$	295,940		$	646,418		$	7,713		$	7,200,623


		For the three months ended June 30, 2025:
					Blood									Total
					Collection			EasyPoint^®			Other			Product
Geographic Segment		Syringes			Products			Needles			Products			Sales
U.S. sales		$	4,859,995			294,829			3,325,272			9,581			8,489,677
North and South America sales (excluding U.S.)			973,020			—			772,416			—			1,745,436
Other international sales			95,514			7,948			97,608			9,550			210,620
Total		$	5,928,529		$	302,777		$	4,195,296		$	19,131		$	10,445,733


		For the six months ended June 30, 2026:
					Blood									Total
					Collection			EasyPoint^®			Other			Product
Geographic Segment		Syringes			Products			Needles			Products			Sales
U.S. sales		$	10,430,295			635,402			742,747			13,401			11,821,845
North and South America sales (excluding U.S.)			1,249,194			—			782,980			600			2,032,774
Other international sales			373,336			35,468			113,896			701			523,401
Total		$	12,052,825		$	670,870		$	1,639,623		$	14,702		$	14,378,020


		For the six months ended June 30, 2025:
					Blood									Total
					Collection			EasyPoint^®			Other			Product
Geographic Segment		Syringes			Products			Needles			Products			Sales
U.S. sales		$	10,998,270			638,662			4,267,790			17,265			15,921,987
North and South America sales (excluding U.S.)			1,526,520			—			772,416			—			2,298,936
Other international sales			363,878			7,947			138,608			9,550			519,983
Total		$	12,888,668		$	646,609		$	5,178,814		$	26,815		$	18,740,906

Schedule of diluted EPS under the treasury stock method

The potential dilution, if any, under the treasury stock method in the three and six month periods ending June 30, 2026 and 2025 is shown on the following schedule:


		Three Months Ended			Three Months Ended			Six Months Ended			Six Months Ended
		June 30, 2026			June 30, 2025			June 30, 2026			June 30, 2025
Net income (loss)		$	2,830,774			(87,471)			(1,394,396)			(10,588,187)
Preferred stock dividend requirements			(57,611)			(57,611)			(115,222)			(115,222)
Income (loss) applicable to common shareholders		$	2,773,163			(145,082)			(1,509,618)			(10,703,409)
Average common shares outstanding			29,937,159			29,937,159			29,937,159			29,937,159
Average common and common equivalent shares outstanding — diluted			29,937,159			29,937,159			29,937,159			29,937,159
Basic earnings (loss) per share		$	0.09			(0.00)			(0.05)			(0.36)
Diluted earnings (loss) per share		$	0.09			(0.00)			(0.05)			(0.36)